Hidradenitis Suppurativa (HS) Recruiting Phase 3 Trials for Secukinumab (DB09029)

Also known as: Hidradenitis Suppurativa / Hidradenitis / Sweat gland inflammation / Acne inversa

IndicationStatusPhase
DBCOND0054533 (Hidradenitis Suppurativa (HS))Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03713619This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).Treatment
NCT03713632Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)Treatment